Healthcare Stock Upgrades for Week Ending Nov. 4th

Wall St. Watchdog reveals information about companies for which stock analysts upgraded shares in the Healthcare sector for the week ending November 4th, 2011.

  • Transcept Pharma (NASDAQ:TSPT): MLV Capital upgraded its rating on this company from Hold to Buy and changed its price target to $21 on Nov 1st. The shares recently traded at $8.39, down $0.13, or 1.53% since the analyst’s rating. About the company: Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company which develops and commercializes proprietary products that address therapeutic needs in the fields of psychiatry and sleep medicine. The Company’s products include sublingual low dose formulation of zolpidem developed for the treatment of insomnia. Get the most recent company news and stock data here >>
  • SurModics (NASDAQ:SRDX): Feltl & Co. upgraded its rating on this company from Hold to Buy and changed its price target to $13 on Nov 2nd. The shares recently traded at $11.04, up $0.35, or 3.27% since the analyst’s rating. About the company: SurModics, Inc. provides surface modification solutions to the medical device industry. The Company’s primary focus is the commercialization of its PhotoLink process through third-party licensing arrangements. SurModics’s process is a light-activated coating technology that modifies medical device surfaces by creating chemical bonds between those surfaces and a variety of chemical agents. Get the most recent company news and stock data here >>
  • Genomic Health (NASDAQ:GHDX): Ladenburg Thalmann upgraded its rating on this company from Neutral to Buy and changed its price target to $26 on Nov 2nd. The shares recently traded at $26.59, up $3.34, or 14.37% since the analyst’s rating. About the company: Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer. The Company’s diagnostic services provide information on the likelihood of disease recurrence and response to certain types of therapy. Get the most recent company news and stock data here >>
  • Myriad Genetics (NASDAQ:MYGN): Ticonderoga upgraded its rating on this company from Neutral to Buy and changed its price target to $25 on Nov 2nd. The shares recently traded at $20.52, down $0.62, or 2.93% since the analyst’s rating. About the company: Myriad Genetics, Inc. develops and markets molecular diagnostic products to provide physicians with information to help guide the care of their patients, to prevent disease, delay the onset of disease, or catch disease at an early stage. Get the most recent company news and stock data here >>

(Note: Selected financial data are sourced from Briefing.com via the Wall St. Journal. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>

More from The Cheat Sheet